Outlook Therapeutics (XTER:41O) Cyclically Adjusted PB Ratio: (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Outlook Therapeutics Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Outlook Therapeutics  (XTER:41O) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Outlook Therapeutics Cyclically Adjusted PB Ratio Related Terms


Outlook Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Outlook Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics Cyclically Adjusted PB Ratio Chart

Outlook Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Outlook Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XTER:41O vs SLGL, SABS, LCTX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Outlook Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Outlook Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Cyclically Adjusted PB Ratio falls into.



Outlook Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Outlook Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Outlook Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.24/330.2130*330.2130
=-0.240

Current CPI (Mar. 2026) = 330.2130.

Outlook Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 9.727 241.018 13.327
201609 -32.231 241.428 -44.084
201612 -140.796 241.432 -192.570
201703 -166.278 243.801 -225.213
201706 -167.260 244.955 -225.476
201709 -180.981 246.819 -242.130
201712 -146.556 246.524 -196.308
201803 -182.484 249.554 -241.465
201806 -25.053 251.989 -32.830
201809 -48.541 252.439 -63.496
201812 -43.543 251.233 -57.232
201903 -42.274 254.202 -54.915
201906 -4.108 256.143 -5.296
201909 -10.241 256.759 -13.171
201912 -14.484 256.974 -18.612
202003 -4.139 258.115 -5.295
202006 1.541 257.797 1.974
202009 0.377 260.280 0.478
202012 -1.354 260.474 -1.717
202103 1.999 264.877 2.492
202106 1.211 271.696 1.472
202109 0.444 274.310 0.534
202112 3.853 278.802 4.563
202203 2.892 287.504 3.322
202206 1.682 296.311 1.874
202209 0.776 296.808 0.863
202212 1.159 296.797 1.289
202303 0.763 301.836 0.835
202306 -0.393 305.109 -0.425
202309 -1.040 307.789 -1.116
202312 -1.715 306.746 -1.846
202403 -5.610 312.332 -5.931
202406 -3.321 314.175 -3.491
202409 -2.754 315.301 -2.884
202412 -1.928 315.605 -2.017
202503 -0.913 319.799 -0.943
202506 -0.742 322.561 -0.760
202509 -0.509 324.800 -0.517
202512 -0.510 324.054 -0.520
202603 -0.240 330.213 -0.240

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Outlook Therapeutics Business Description

Other Exchanges OTLK:USA41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.